205 related articles for article (PubMed ID: 29557941)
1. Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis.
Huyut Z; Bakan N; Yıldırım S; Alp HH
Med Sci Monit Basic Res; 2018 Mar; 24():47-58. PubMed ID: 29557941
[TBL] [Abstract][Full Text] [Related]
2. Zaprinast and avanafil increase the vascular endothelial growth factor, vitamin D
Huyut Z; Bakan N; Akbay Hİ; Yıldırım S; Şekeroğlu MR
Arch Physiol Biochem; 2022 Oct; 128(5):1290-1296. PubMed ID: 32421396
[No Abstract] [Full Text] [Related]
3. Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs.
Porwal K; Pal S; Bhagwati S; Siddiqi MI; Chattopadhyay N
Eur J Pharmacol; 2021 May; 899():174015. PubMed ID: 33711307
[TBL] [Abstract][Full Text] [Related]
4. Zaprinast impairs spatial memory by increasing PDE5 expression in the rat hippocampus.
Giorgi M; Pompili A; Cardarelli S; Castelli V; Biagioni S; Sancesario G; Gasbarri A
Behav Brain Res; 2015 Feb; 278():129-36. PubMed ID: 25281278
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors.
Matot I; Gozal Y
Chest; 2004 Feb; 125(2):644-51. PubMed ID: 14769749
[TBL] [Abstract][Full Text] [Related]
6. Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis.
Sequetto PL; Gonçalves RV; Pinto AS; Oliveira MGA; Maldonado IRSC; Oliveira TT; Novaes RD
Microsc Microanal; 2017 Oct; 23(5):989-1001. PubMed ID: 28743325
[TBL] [Abstract][Full Text] [Related]
7. An update on glucocorticoid-induced osteoporosis.
Woolf AD
Curr Opin Rheumatol; 2007 Jul; 19(4):370-5. PubMed ID: 17551369
[TBL] [Abstract][Full Text] [Related]
8. Denosumab in the treatment of glucocorticoid-induced osteoporosis.
Coskun Benlidayi I
Rheumatol Int; 2018 Nov; 38(11):1975-1984. PubMed ID: 30019224
[TBL] [Abstract][Full Text] [Related]
9. Anabolic therapy in glucocorticoid-induced osteoporosis.
Sambrook PN
N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
[No Abstract] [Full Text] [Related]
10. Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat.
Carceles MD; Aleixandre F; Fuente T; López-Vidal J; Laorden ML
Eur J Anaesthesiol; 2003 Mar; 20(3):205-11. PubMed ID: 12650491
[TBL] [Abstract][Full Text] [Related]
11. Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine.
Ren H; Shen G; Tang J; Qiu T; Zhang Z; Zhao W; Yu X; Huang J; Liang D; Yao Z; Yang Z; Jiang X
Sci Rep; 2017 Sep; 7(1):10617. PubMed ID: 28878388
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid-induced osteoporosis and parathyroid hormone.
Carpinteri R; Porcelli T; Mejia C; Patelli I; Bilezikian JP; Canalis E; Angeli A; Giustina A; Mazziotti G
J Endocrinol Invest; 2010; 33(7 Suppl):16-21. PubMed ID: 20938221
[TBL] [Abstract][Full Text] [Related]
13. Influence of glucocorticoid on bone in 3-, 6-, and 12-month-old rats as determined by bone mass and histomorphometry.
Ogoshi T; Hagino H; Fukata S; Tanishima S; Okano T; Teshima R
Mod Rheumatol; 2008; 18(6):552-61. PubMed ID: 18648735
[TBL] [Abstract][Full Text] [Related]
14. Curcumin improves bone microarchitecture in glucocorticoid-induced secondary osteoporosis mice through the activation of microRNA-365 via regulating MMP-9.
Li G; Bu J; Zhu Y; Xiao X; Liang Z; Zhang R
Int J Clin Exp Pathol; 2015; 8(12):15684-95. PubMed ID: 26884838
[TBL] [Abstract][Full Text] [Related]
15. Can zaprinast and avanafil induce the levels of angiogenesis, bone morphogenic protein 2, 4 and 7 in kidney of ovariectomised rats?
Huyut Z; Bakan N; Yıldırım S; Akbay Hİ; Huyut MT; Ahlatçı A; Uçar B
Arch Physiol Biochem; 2022 Aug; 128(4):945-950. PubMed ID: 32207349
[TBL] [Abstract][Full Text] [Related]
16. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
[TBL] [Abstract][Full Text] [Related]
18. Effects of the combined Herba Epimedii and Fructus Ligustri Lucidi on bone turnover and TGF-β1/Smads pathway in GIOP rats.
Yang Y; Nian H; Tang X; Wang X; Liu R
J Ethnopharmacol; 2017 Apr; 201():91-99. PubMed ID: 28254481
[TBL] [Abstract][Full Text] [Related]
19. The effect of isoenzyme-selective PDE inhibitors on methacholine-induced contraction of guinea-pig and rat ileum.
Tomkinson A; Raeburn D
Br J Pharmacol; 1996 Aug; 118(8):2131-9. PubMed ID: 8864552
[TBL] [Abstract][Full Text] [Related]
20. One year in review 2018: progress in osteoporosis treatment.
Figliomeni A; Signorini V; Mazzantini M
Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
